D.W.W. Newling - Concepedia

Author

D.W.W. Newling

Also Known As

D Newling, D W Newling, D. Newling, D. W. Newling, D. W. W. NEWLING, D. W. W. Newling, D.W. Newling, D.W.W Newling, D.W.W. Newling, Don W.W. Newling

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

St James's University Hospital ZNA Middelheim Hospital European Organisation for Research and Treatment of Cancer Vrije Universiteit Amsterdam University of Amsterdam

About

D.W.W. Newling is an author at St James's University Hospital specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	966
2	Health Sciences	2	2	251
3	Endocrinology	2	2	181
4	Cell Biology	1	1	30
5	Obstetrics	1	1	168

D.W.W. Newling

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853) L. Denis, Jandeilson L. Moura, Aldo Bono, Urology MedicineGoserelin AcetateSurgeryPhase Iii	1993	259
Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853 L. Denis, F. Keuppens, P. H. SMITH, European Urology Endocrine OncologyMaximal Androgen BlockadeOncologyHealth SciencesMedicine	1998	168
The Final Analysis of the EORTCGenito-Urinary T ract CancerCo-Operative Group Phase IIIClinical Trial (Protocol 30805)Comparing Orchidectomy,Orchidectomy plus CyproteroneAcetate and Low Dose Stilboestrolin the Management of MetastaticCarcinoma of the Prostate M. R. G. Robinson, P. H. SMITH, B. Richards, European Urology	1995	103
Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer E.H. Cooper, T G Armitage, M. R. G. Robinson, Cancer UrologyOncologySurgical OncologyGenitourinary CancerMedicine	1990	86
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853 D.W.W. Newling, L. Denis, K. Vermeylen Cancer Surgical OncologyCancer–-genitourinary GroupCancer ManagementTrial 30853Pathology	1993	83
The Value of the Measurement of Serum Prostate Specific Antigen in Patients with Benign Prostatic Hyperplasia and Untreated Prostate Cancer T G Armitage, E.H. Cooper, D.W.W. Newling, British Journal of Urology	1988	80
Treatment of Invasive Bladder Cancer by Local Resection and High Dose Methotrexate R. Hall, D.W.W. Newling, Peter Ramsden, British Journal of Urology	1984	76
An Evaluation of the Immunochemical Measurement ofProstatic Acid Phosphatase and Prostatic Specific Antigen inCarcinoma of the Prostate J.K. Siddall, E.H. Cooper, D.W.W. Newling, European Urology	1986	72
Adjuvant Chemotherapy with Doxorubicin (Adriamycin) and 5–Fluorouracil in T3, NX, MO Bladder Cancer Treated with Radiotherapy B. Richards, J. R. G. BASTABLE, Laurence S. Freedman, British Journal of Urology	1983	69
Casodex<sup>TM</sup> 10&ndash;200&nbsp;mg Daily, Used as Monotherapy for the Treatment of Patients with Advanced Prostate Cancer C. Tyrrell, L. Denis, D.W.W. Newling, European Urology UrologyMedicinePharmacologyMg DailyAdvanced Prostate Cancer	1998	62

Page 1